1. Home
  2. ALT vs EIC Comparison

ALT vs EIC Comparison

Compare ALT & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • EIC
  • Stock Information
  • Founded
  • ALT 1997
  • EIC N/A
  • Country
  • ALT United States
  • EIC United States
  • Employees
  • ALT N/A
  • EIC N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • EIC Finance/Investors Services
  • Sector
  • ALT Health Care
  • EIC Finance
  • Exchange
  • ALT Nasdaq
  • EIC Nasdaq
  • Market Cap
  • ALT 292.0M
  • EIC 348.9M
  • IPO Year
  • ALT N/A
  • EIC 2019
  • Fundamental
  • Price
  • ALT $3.83
  • EIC $13.86
  • Analyst Decision
  • ALT Strong Buy
  • EIC Strong Buy
  • Analyst Count
  • ALT 6
  • EIC 1
  • Target Price
  • ALT $17.40
  • EIC $17.50
  • AVG Volume (30 Days)
  • ALT 3.0M
  • EIC 233.8K
  • Earning Date
  • ALT 08-12-2025
  • EIC 08-12-2025
  • Dividend Yield
  • ALT N/A
  • EIC 11.24%
  • EPS Growth
  • ALT N/A
  • EIC N/A
  • EPS
  • ALT N/A
  • EIC 0.70
  • Revenue
  • ALT $20,000.00
  • EIC $55,581,156.00
  • Revenue This Year
  • ALT N/A
  • EIC $37.84
  • Revenue Next Year
  • ALT $761,880.20
  • EIC $23.33
  • P/E Ratio
  • ALT N/A
  • EIC $19.94
  • Revenue Growth
  • ALT N/A
  • EIC 56.39
  • 52 Week Low
  • ALT $2.90
  • EIC $12.10
  • 52 Week High
  • ALT $11.16
  • EIC $16.71
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • EIC 70.39
  • Support Level
  • ALT $3.35
  • EIC $12.10
  • Resistance Level
  • ALT $3.66
  • EIC $13.15
  • Average True Range (ATR)
  • ALT 0.19
  • EIC 0.18
  • MACD
  • ALT 0.07
  • EIC 0.13
  • Stochastic Oscillator
  • ALT 86.18
  • EIC 97.37

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: